英夫利西单抗与阿达木单抗治疗瘘管型克罗恩病:来自前瞻性澳大利亚国家IBD队列(PANIC4)研究的倾向性评分匹配分析
基于澳大利亚药品福利计划2005—2021年登记数据,分析瘘管型克罗恩病患者中英夫利西单抗与阿达木单抗的持续性。倾向性评分匹配后,生物制剂初治患者中英夫利西单抗的总体及无皮质类固醇持续性的优于阿达木单抗,生物制剂经治患者中无差异;硫嘌呤联合治疗与改善持续性独立相关。
要点
- 生物制剂初治瘘管型克罗恩病患者中,英夫利西单抗总体及无皮质类固醇持续性的优于阿达木单抗。
- 生物制剂经治患者中,两种药物的总体持续性无显著差异。
- 硫嘌呤联合诱导治疗与改善的总体及无皮质类固醇持续性独立相关。
核心结论
- 真实世界数据显示,在生物制剂初治的瘘管型克罗恩病患者中,英夫利西单抗的持续性优于阿达木单抗。
- 在生物制剂经治的瘘管型克罗恩病患者中,未显示两种药物存在治疗差异。
- 硫嘌呤联合治疗与改善的生物制剂持续性独立相关。
研究设计与样本
- 基于澳大利亚药品福利计划登记数据2005—2021年的持续性分析。
- 纳入瘘管型克罗恩病的所有配发生物制剂,共5739个治疗线,涉及4466例患者,随访17144患者年。
- 采用倾向性评分匹配以校正基线队列不平衡。
主要发现
- 5739个治疗线中,2605个(45.4%)使用阿达木单抗,3134个(54.6%)使用英夫利西单抗。
- 1697个(29.6%)在诱导时使用硫嘌呤联合治疗,242个(4.2%)使用甲氨蝶呤。
- 生物制剂初治患者中,英夫利西单抗总体持续性优于阿达木单抗(P=0.0002),无皮质类固醇持续性亦优于阿达木单抗(P=0.0021)。
- 生物制剂经治患者中,两种药物总体持续性无差异(P=0.064),英夫利西单抗无皮质类固醇持续性更优(P=0.030)。
- 硫嘌呤联合诱导与改善的总体持续性(P=0.0002)和无皮质类固醇持续性(P=0.045)相关;甲氨蝶呤未见差异。
关键数值与推荐
- 倾向性评分匹配后,生物制剂初治患者中英夫利西单抗总体持续性优于阿达木单抗(P<0.0001),无皮质类固醇持续性亦优于阿达木单抗(P=0.0016)。
- 倾向性评分匹配后,生物制剂经治患者中两种药物总体持续性(P=0.12)和无皮质类固醇持续性(P=0.074)均无显著差异。
- 倾向性评分匹配后,硫嘌呤与更优的总体及无皮质类固醇持续性相关,甲氨蝶呤未见差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: There are spare data on comparative medication efficacy in fistulizing Crohn's disease (FCD), particularly with immunomodulator cotherapy. Persistence is a unique way to assess real-world outcomes. METHODS: The persistence of all dispensed biological agents was analyzed from the Australian Pharmaceutical Benefits Scheme registry data 2005-2021 for FCD. Propensity score matching was performed to account for baseline cohort imbalance. RESULTS: There were 5,739 lines of therapy in 4,466 patients over the 16-year period with 17,144 patient-years of follow-up; through therapy, 2,605 of 5,739 (45.4%) used adalimumab, and 3,134 of 5,739 (54.6%) used infliximab; 1,697 of 5,739 (29.6%) used thiopurine cotherapy at induction, while 242 of 5,739 (4.2%) used methotrexate. As a first-line biologic (biologic-naive), infliximab showed superior overall and corticosteroid-free persistence to adalimumab ( P = 0.0002 and P = 0.0021, respectively). Used after first-line (biologic-exposed), there was no difference between agents for overall persistence ( P = 0.064), although infliximab showed greater corticosteroid-free persistence ( P = 0.030). Coinduction with thiopurine was associated with improved overall and corticosteroid-free persistence ( P = 0.0002 and P = 0.045, respectively). After propensity score matching, infliximab showed superior overall and corticosteroid-free persistence compared with adalimumab in bio-naive ( P < 0.0001 and P = 0.0016, respectively), not in bio-exposed patients ( P = 0.12 and P = 0.074, respectively). Thiopurine was associated with superior overall and corticosteroid-free persistence use, although no difference was seen with methotrexate. DISCUSSION: The Persistence Australia National IBD Cohort with real-world data of nonhierarchical prescribing of biological agents supports the superiority of infliximab over adalimumab in bio-naive patients with FCD, but did not show a therapeutic difference in bio-exposed FCD. Thiopurine cotherapy was independently associated with improved biological agent persistence in FCD.
引用
- Chetwood JD, Paramsothy S, Leong RW, et al. Infliximab and Adalimumab in the Treatment of Fistulizing Crohn's Disease: A Propensity Score-Matched Analysis From the Prospective Persistence Australian National IBD Cohort (PANIC4) Study. Am J Gastroenterol. 2024. PMID: 39787365. doi:10.14309/ajg.0000000000003271
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。